Arbitel Trio Tablets contain Telmisartan 40 mg, Cilnidipine 10 mg, and Metoprolol Succinate 25 mg/50 mg.

Arbitel Trio Tablets combine the complementary antihypertensive actions of Telmisartan, Cilnidipine, and Metoprolol Succinate in a convenient once-daily formulation. Telmisartan provides renin-angiotensin system blockade by selectively inhibiting the AT1 receptor, Cilnidipine offers dual calcium channel blockade with potent vasodilatory effects, and Metoprolol Succinate, a cardioselective beta1-blocker, reduces heart rate, cardiac output, and renin release. This triple-drug combination provides comprehensive blood pressure control and is intended for patients with uncontrolled essential hypertension requiring multi-drug therapy.

Arbitel Trio Tablets are indicated for the treatment of uncontrolled essential hypertension in patients requiring combination therapy with three antihypertensive agents.

Telmisartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor in vascular smooth muscle and the adrenal gland, thereby reducing vasoconstriction and aldosterone secretion. Metoprolol Succinate is a selective beta1-adrenergic receptor blocker that lowers blood pressure by reducing cardiac output, suppressing sympathetic activity, and decreasing renin release. Cilnidipine is a dihydropyridine calcium channel blocker that inhibits calcium influx into vascular smooth muscle, producing vasodilation with high vascular selectivity and contributing to effective blood pressure reduction.

The recommended dosage is one tablet orally once daily, or as directed by the physician.

Arbitel Trio Tablets are contraindicated in patients with known hypersensitivity to Telmisartan, Cilnidipine, Metoprolol Succinate, or any component of the formulation. They are also contraindicated in patients with severe bradycardia, second- or third-degree heart block, cardiogenic shock, decompensated cardiac failure, sick sinus syndrome, and severe hepatic impairment.